What is HC Wainwright’s Estimate for VTYX FY2024 Earnings?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – HC Wainwright lifted their FY2024 earnings estimates for Ventyx Biosciences in a research report issued to clients and investors on Tuesday, January 14th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($2.18) per share for the year, up from their previous forecast of ($2.19). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Ventyx Biosciences’ Q1 2025 earnings at ($0.71) EPS, Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($1.98) EPS and FY2028 earnings at ($1.56) EPS.

Separately, Oppenheimer reiterated an “outperform” rating and set a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Ventyx Biosciences Stock Up 6.9 %

Ventyx Biosciences stock opened at $2.02 on Friday. Ventyx Biosciences has a 52-week low of $1.67 and a 52-week high of $11.48. The firm has a market capitalization of $142.83 million, a price-to-earnings ratio of -0.86 and a beta of 0.55. The firm has a 50-day moving average price of $2.27 and a two-hundred day moving average price of $2.27.

Institutional Trading of Ventyx Biosciences

A number of large investors have recently added to or reduced their stakes in VTYX. Deerfield Management Company L.P. Series C lifted its position in shares of Ventyx Biosciences by 64.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after acquiring an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC boosted its position in shares of Ventyx Biosciences by 153.2% in the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the period. Vestal Point Capital LP raised its holdings in Ventyx Biosciences by 31.2% during the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after buying an additional 410,000 shares during the period. Geode Capital Management LLC lifted its stake in Ventyx Biosciences by 5.9% during the third quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company’s stock valued at $3,034,000 after buying an additional 77,350 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Ventyx Biosciences by 0.8% in the third quarter. State Street Corp now owns 1,187,650 shares of the company’s stock worth $2,589,000 after buying an additional 9,783 shares during the period. 97.88% of the stock is currently owned by institutional investors.

Insider Transactions at Ventyx Biosciences

In related news, insider John Nuss sold 13,161 shares of the firm’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the completion of the transaction, the insider now owns 485,701 shares of the company’s stock, valued at $1,097,684.26. This trade represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Raju Mohan purchased 261,752 shares of the company’s stock in a transaction on Monday, November 25th. The stock was acquired at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the completion of the transaction, the chief executive officer now owns 2,175,028 shares of the company’s stock, valued at $4,371,806.28. This represents a 13.68 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 630,000 shares of company stock valued at $1,262,415. Company insiders own 18.18% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.